If weight loss is a priority Semaglutide is FDA-approved for managing weight in patients with obesity and overweight
4.4 Cardiovascular and respiratory clinical manifestations Approximately half of patients with L-C19 reported incomplete recovery, with shortness of breath and other respiratory problems (87), that included chest pain, cough, or sputum production (88)
[Translated from marnys.es] Extra energy for training sessions
Insurance companies may use these guidelines or specific criteria to provide coverage. Doctors and drug manufacturers do not recommend these medicines for anyone who: Has a history of pancreatitis or medullary thyroid cancer Has multiple endocrine neoplasia syndrome type 2 (MEN2) Is pregnant, attempting to conceive or breastfeeding There are no restrictions on who can prescribe them
Summary: Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials for obesity and type 2 diabetes but not yet approved by the MHRA, EMA, or FDA
